Gentium Promotes Salvatore Calabrese To Chief Financial Officer
VILLA GUARDIA, Italy, Dec. 2, 2010 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that Mr. Salvatore Calabrese, Senior Vice President, Finance, has been promoted to Chief Financial Officer effective December 1, 2010. Mr. Calabrese will continue to retain his title as Senior Vice President.
Mr. Calabrese joined the Company in February 2005 as Vice President, Finance and Secretary and was promoted to Senior Vice President, Finance in February 2010. Prior to joining the Company, Mr. Calabrese worked as an Accounting and Finance Manager for Novuspharma S.p.A., a subsidiary of Nasdaq-listed Cell Therapeutics, Inc., that focuses on the discovery and development of cancer drugs. Prior to working at Novuspharma, Mr. Calabrese was a Manager for PricewaterhouseCoopers, where he was employed for seven years working in Milan, Italy and Boston, MA.
Commenting on the announcement, Dr. Khalid Islam, Chairman and Chief Executive Officer of Gentium said, "Mr. Calabrese has exemplified strong leadership and talent in his various roles at the Company. In addition, with his knowledge of the Company's business and experience in healthcare, finance and business strategy, Mr. Calabrese continues to be a valuable asset to the Company. I look forward to continuing to work with Mr. Calabrese as we move forward on executing our regulatory and commercial strategies and our plan for future growth."About Gentium Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD, and Fast Track Designation by the U.S. FDA to treat VOD.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV